Data Sheet 3_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 1_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 8_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 5_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 2_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 10_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 12_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 6_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Mitotic phenotypes caused by co-depletion of CAMSAP2 and HAUS6. by Naoko Nishizawa (20536299)

“…MW (kDa) is shown in the left. Mean ± SD from 3 independent experiments. n.s.: P > 0.05, Student’s t-test. …”

Table 1_New serum soluble factors predicting inflammatory and non-inflammatory disability worsening in multiple sclerosis.doc by Alexander Rodero-Romero (20172186)

“…Q-values below 0.05 were considered as significant.</p>Results<p>Compared with HC, patients with low sGFAP concentrations exhibited decreased levels of granulocyte-macrophage colony stimulating factor (GM-CSF), a cytokine inducing innate cell activation q=0.009 for NLGL and q=0.002 for NHGL groups). …”

Table 1_Assessment of brain atrophy as a promising marker of radiological activity in patients with relapsing–remitting multiple sclerosis.docx by Aleksandra Pogoda-Wesołowska (14589242)

“…In the year-to-year analysis (n_CLAD = 59, n_ALEM = 36) within the CLAD group, new T2 lesions were significantly associated with a decrease in thalamic (p = 0.02), cerebellum (p = 0.05) and deep grey matter (p = 0.05) volume. …”

Image 1_The role of Sophora alopecuroides alkaloids in colon health of lambs fed high-concentrate diets for extended periods: impact on barrier function, antioxidation, and microfl... by Shufang Li (3183168)

“…The concentration of propionate and lactate in colon contents in HC group increased significantly, while the pH decreased significantly (p < 0.05). …”

Fig files for contractility paper by Kieran Boniface (18291901)

“…We find that introducing a strain-adaptive feedback into the contractility force acts to both effectively stiffen the tissue and to decrease its apparent compressibility, with the feedback sensitivity determining the new effective stiffness. …”

<b>Mechanisms of Modified Qinghao Biejia Decoction in Reversing Drug Resistance in K562/ADM Cells via Autophagy Inhibition</b> (Supplementar data).xlsx by Jamal Khan (20551934)

“…The mean fluorescence intensity of MDC, which measures the level of autophagic vacuoles, was significantly decreased in the FG and FG+3MA groups, which implies a decrease in autophagic flux. …”

Table 1_Quantification of weekly strength-training volume per muscle group in competitive physique athletes.xlsx by Thiago Beraldo da Silveira (21818603)

“…We suggest new studies that can help with developing more detailed training practices for physique athletes.…”

Cilia disassembly proceeds at a faster rate in CCDC66-depleted cells, which is regulated by the AurkA-HDAC6 axis and rescued by microtubule stabilization. by Jovana Deretic (13113617)

“…Cilia length was quantified in 3D according to ARL13b signal (co-localizing with acetylated-tubulin). The mean cilia length in CCDC66-depleted cells decreased to 0.74-fold compared to the mean control length at 0 h. …”